Wells Fargo & Company MN trimmed its position in Akorn, Inc. (NASDAQ:AKRX) by 83.3% during the third quarter, HoldingsChannel.com reports. The firm owned 99,035 shares of the company’s stock after selling 494,082 shares during the quarter. Wells Fargo & Company MN’s holdings in Akorn were worth $3,288,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of AKRX. Legal & General Group Plc grew its stake in Akorn by 17.6% in the 3rd quarter. Legal & General Group Plc now owns 78,148 shares of the company’s stock valued at $2,594,000 after buying an additional 11,689 shares during the last quarter. FNY Partners Fund LP acquired a new position in Akorn in the 3rd quarter valued at about $371,000. Great West Life Assurance Co. Can grew its stake in Akorn by 8.6% in the 3rd quarter. Great West Life Assurance Co. Can now owns 56,302 shares of the company’s stock valued at $1,867,000 after buying an additional 4,455 shares during the last quarter. LMR Partners LLP acquired a new position in Akorn in the 3rd quarter valued at about $200,000. Finally, American International Group Inc. grew its stake in Akorn by 7.3% in the 3rd quarter. American International Group Inc. now owns 191,666 shares of the company’s stock valued at $6,361,000 after buying an additional 13,109 shares during the last quarter. 73.44% of the stock is currently owned by institutional investors.
Akorn, Inc. (NASDAQ AKRX) opened at $33.51 on Thursday. Akorn, Inc. has a 52-week low of $17.74 and a 52-week high of $34.00. The stock has a market cap of $4,190.00, a P/E ratio of 56.80, a price-to-earnings-growth ratio of 1.67 and a beta of 1.33. The company has a current ratio of 4.16, a quick ratio of 3.17 and a debt-to-equity ratio of 0.92.
In other Akorn news, Director Brian Tambi sold 15,100 shares of the stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $33.35, for a total transaction of $503,585.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 28.20% of the company’s stock.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Want to see what other hedge funds are holding AKRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akorn, Inc. (NASDAQ:AKRX).
What are top analysts saying about Akorn? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Akorn and related companies.